尿路感染症に対するTazobactam/Piperacillinの臨床的検討

• 松本 哲朗他

  九州大学医学部泌尿器科

書誌事項

タイトル別名

• Clinical study of tazobactam/piperacillin in urinary tract infections

抄録

The clinical efficacy and safety of the combined antibiotic agent tazobactam/piperacillin (TAZ/PIPC) were studied by the administration of TAZ/PIPC to 88 patients diagnosed with urinary tract infections (UTI).<BR>Tazobactam (TAZ) is a newly synthesized β-lactamase inhibitor and piperacillin (PIPC) is an antibiotic of penicillin group with broad antibacterial spectrum.<BR>1) Clinical results: The administration method was intravenous injection or drip infusion at the dose of 2.5-5.0g, twice a day for 3-9 days. Of the 88 cases, 65 cases with complicated UTI were evaluated according to the criteria of the Japanese UTI Committee. The clinical response was excellent in 21, moderate in 31, poor in 13, a clinical efficacy rate of 80.0%.<BR>In the cases of monomicrobial infection, the efficacy rate was 83.8%, while in those of polymicrobial infection, the efficacy rate was 75.0%. The bacteriological eradicated rate was 83.7%(87/104) in all strains, and 80.7%(46/57) in β-lactamase producing strains.<BR>2) Safety: Concerning adverse reactions, diarrhea was observed in two patients, and rash, urticaria and sudation, soft stool and pyrosis in one each, a total of five patients. Slight abnormal laboratory findings were observed in ten patients.

収録刊行物

• ＣＨＥＭＯＴＨＥＲＡＰＹ

  ＣＨＥＭＯＴＨＥＲＡＰＹ 42 (Supplement2), 774-781, 1994

  公益社団法人 日本化学療法学会

キーワード

• 臨床的検討

詳細情報

• CRID: 1390001206285256448
• NII論文ID: 130004198649
• DOI: 10.11250/chemotherapy1953.42.supplement2_774
• ISSN: 18845894
• ISSN: 00093165
• データソース種別:
  • JaLC
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可